Welcome to our dedicated page for Airsculpt Technologies SEC filings (Ticker: AIRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AirSculpt Technologies, Inc. filings document the regulatory record of a public medical aesthetics company that provides premium body contouring procedures. Its 8-K reports cover operating and financial results, preliminary updates, non-GAAP financial measures, reconciliations, debt and capital-structure disclosures, material agreements, and governance events.
Proxy materials describe annual meeting matters, director elections, shareholder voting items, board structure, and related governance disclosures. Other filings include late-filing notices tied to annual report timing, amendments correcting non-GAAP presentation, and emerging growth company status under SEC reporting rules.
AirSculpt Technologies, Inc. received an updated Schedule 13G/A from a group of Vesey Street Capital–affiliated investors led by Adam T. Feinstein reporting significant beneficial ownership of its common stock. The filing is based on 72,095,209 shares of common stock outstanding as of August 7, 2026.
EBS Aggregator Blocker Holdings, LLC reports beneficial ownership of 11,761,462 shares, or 16.3% of the class, including shares over which it may be deemed to share voting power through a Proxy and Voting Agreement with Thrivent White Rose Fund XI Equity Direct, L.P. VSCP EBS Aggregator, L.P. reports 14,038,819 shares (19.5%), and Vesey Street Capital Partners Healthcare Fund-A, L.P. reports 4,523,899 shares (6.3%), each with shared voting and dispositive power over their directly held shares.
Adam T. Feinstein and Vesey Street Capital Partners, L.L.C. each report beneficial ownership and shared voting power over 30,324,180 shares, or 42.1% of the class, reflecting their control relationships with the Vesey-affiliated entities and shared voting rights over 5,169,820 Thrivent shares. Each reporting person disclaims beneficial ownership beyond their pecuniary interest.
AirSculpt Technologies, Inc. disclosed that its Board of Directors approved relocating the company’s corporate headquarters. The headquarters will move from 1111 Lincoln Road, Suite 802, Miami Beach, Florida 33139 to 2023 West Platt Street, Tampa, Florida 33605, effective for corporate records and reporting purposes.
The new Tampa address will appear in the company’s future periodic reports and other filings with the Securities and Exchange Commission. No operational, financial, or transactional terms are described beyond this change of corporate headquarters address.
Thrivent Financial for Lutherans and its affiliate Thrivent Investment Capital Advisors, LLC (TICA) report beneficial ownership of 4,425,000 shares of Airsculpt Technologies, Inc. common stock, representing 6.3% of the class. These shares are held directly by Thrivent White Rose Fund XI Equity Direct, L.P.
The filing states no sole voting or dispositive power and shared voting and dispositive power over 4,425,000 shares. On May 20, 2026, White Rose appointed Vesey Street Capital Partners, L.L.C. as proxy agent with voting power over these shares for a limited period, while TICA acts as investment adviser with shared authority to vote and dispose of the holdings.
AirSculpt Technologies, Inc. reported modestly lower activity and continued losses for the three and six months ended June 30, 2026. Revenue was $42.9 million for the quarter and $82.3 million year‑to‑date, down slightly from the prior‑year periods as cases were essentially flat while revenue per case declined. Q2 net loss was $1.1 million and first‑half net loss was $3.5 million, or $(0.02) and $(0.05) per share, respectively. Adjusted EBITDA remained positive at $4.9 million in Q2 and $8.2 million for the first half, but margins compressed.
The company ended June 30, 2026 with $18.8 million of cash and $43.6 million of term debt (net), after voluntary prepayments and equity raises via an at‑the‑market program that generated $19.6 million in first‑half net proceeds. Interest expense declined as debt was reduced, while advertising expense and customer acquisition costs increased, pressuring profitability. A Fourth Amendment to the credit agreement subsequently extended maturities to November 15, 2027 and added mandatory prepayments and enhanced lender reporting.
Management continues to report material weaknesses in internal control over financial reporting, including general accounting processes and lease accounting under ASC 842; remediation efforts are underway but not yet completed.
AirSculpt Technologies, Inc. reported softer second-quarter 2026 results while highlighting modest operational stability and debt reduction. Q2 revenue was $42.9 million, down from $44.0 million a year earlier, with case volume essentially flat at 3,376 and revenue per case slightly lower. The company recorded a net loss of $1.1 million versus a $0.6 million loss in Q2 2025, and Adjusted EBITDA declined to $4.9 million from $5.8 million, reducing Adjusted EBITDA margin to 11.5% from 13.3%.
For the first six months of 2026, revenue was $82.3 million and net loss $3.5 million, both similar to 2025, while Adjusted EBITDA fell to $8.2 million. Same-center case volume grew about 1% in Q2 and year-to-date, but same-center revenue per case decreased. Management reaffirmed 2026 revenue at the lower end of its $151–$157 million guidance range and reduced its Adjusted EBITDA outlook to $12–$14 million.
Liquidity improved, with $18.8 million of cash and gross debt of $44.2 million as of June 30, 2026, reflecting roughly $30 million of gross debt reduction and about $10 million higher cash since the start of 2025. The company amended its term loan to extend maturity to November 2027, made a $2.5 million payment at signing, committed to another $2.5 million by September 30, 2026, and earmarked 50% of future equity issuance net proceeds for additional prepayments.
AirSculpt Technologies, Inc. Schedule 13G discloses that Aaron Rollins beneficially owns 14,721,062 shares of the issuer's common stock. The filing states this represents 20.9% of the class, calculated using 70,545,681 shares outstanding as of May 7, 2026 per the company's Form 10-Q for the period ended March 31, 2026. The filing lists sole voting and dispositive power over the same 14,721,062 shares and is signed by Mr. Rollins on June 1, 2026.
Airsculpt Technologies, Inc. disclosed that an entity associated with major holder Adam T. Feinstein reported an internal share transfer involving its common stock. On May 20, 2026, EBS Aggregator Blocker Holdings, LLC made a distribution in-kind of 5,169,820 shares of common stock for no consideration to Thrivent White Rose Fund XI Equity Direct, L.P., under a prior letter agreement. The filing characterizes this as an "other" type transaction rather than a market purchase or sale. Following the reported transactions, indirect holdings include 4,523,899 shares by Vesey Street Capital Partners Healthcare Fund-A, LP, 14,038,819 shares by VSCP EBS Aggregator, L.P., and 6,591,642 shares by EBS Aggregator Blocker Holdings, LLC.
Higgins Kenneth reported acquisition or exercise transactions in this Form 4 filing.
Airsculpt Technologies, Inc. director Kenneth Higgins received an award of 100,286 shares of Common Stock in the form of Restricted Stock Units on May 12, 2026. These RSUs vest on the earlier of the first anniversary of grant or the day before the next annual stockholder meeting, subject to his continued service with the company.
Following this award, Higgins directly holds 274,066 shares of Airsculpt Technologies Common Stock as reported in the filing.
Aaron Thomas J reported acquisition or exercise transactions in this Form 4 filing.
Airsculpt Technologies director Aaron Thomas reported receiving a grant of 100,286 shares of Common Stock in the form of Restricted Stock Units on May 12, 2026. This is a compensation-related award at no cash cost per share, not an open-market purchase.
The RSUs will vest upon the earlier of the first anniversary of the grant date or the day before the next annual meeting of stockholders, provided he continues serving the company. Following this grant, Thomas holds 276,866 shares directly, showing this is a sizeable but routine equity award for a director.
Airsculpt Technologies, Inc. director Caroline Chu received an equity grant in the form of restricted stock units. She was awarded 100,286 shares of Common Stock on May 12, 2026 as a grant/award acquisition at a stated price of $0.00 per share, reflecting stock-based compensation rather than a market purchase.
According to the filing, her direct holdings increased to 277,066 shares of Common Stock after the award. The RSUs will vest upon the earlier of the first anniversary of the grant date or the day prior to the next annual meeting of stockholders, contingent on her continued service with the company.